Blog

May 23, 2024, 09:20

Yakup Ergün Summarizes Final Results of RIGHT Choice

Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on X:

“Final results of RIGHT Choice: Ribociclib plus ET vs ChT in premenopausal women with clinically aggressive HR+/HER2− aBC

47.7% patients had investigator-assessed visceral crisis

R+ET vs ChT
mPFS -> 21.8 vs 12.8 mo
ORR -> 66.1% vs 61.8%.”

Proceed to the article.
Source: Yakup Ergün/X
.

aBC Ankara Numune Training and Research Hospital cancer cancer treatment outcomes chemotherapy endocrine therapy HR+/HER2− advanced breast cancer median progression-free survival medical oncologist mPFS OncoDaily Oncology oncology research ORR overall response rate premenopausal women Research Ribociclib RIGHT Choice trial visceral crisis Yakup Ergün

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage